25th week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130156765 | FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS - The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity. | 2013-06-20 |
20130156766 | TREATMENT OF DRY AGE RELATED MACULAR DEGENERATION - A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent. | 2013-06-20 |
20130156767 | METHOD FOR TREATING CACHEXIA USING ANTAGONIST ANTIBODIES AGAINST GDF-8 - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2013-06-20 |
20130156768 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH BRAF INHIBITORS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2013-06-20 |
20130156769 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 2013-06-20 |
20130156770 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 2013-06-20 |
20130156771 | FDF03 ANTIBODIES AND USES THEREOF - The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer. | 2013-06-20 |
20130156772 | Bispecific Anti ErbB1 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 2013-06-20 |
20130156773 | LUNG REGENERATION USING CORD BLOOD-DERIVED HEMATOPOIETIC STEM CELLS - Described herein are novel approaches for regenerating injured or defective lung epithelium for the treatment of respiratory disorders using, in part, cord blood-derived hematopoietic stem cells. The methods and uses described herein relate to the administration of or use of hematopoietic stem cells, specifically those isolated or enriched from umbilical cord blood, to a subject in need thereof having a respiratory disorder, such as BPD, or any disorder characterized by insufficient or defective or injured lung epithelium or lung vasculature. | 2013-06-20 |
20130156774 | BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS - Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer. | 2013-06-20 |
20130156775 | CHLAMYDIA TRACHOMATIS ANTIGENS - Proteins encoded by | 2013-06-20 |
20130156776 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND MODULATING STRESS GRANULE FORMATION - The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors. The invention also provides methods for screening for agents for treating or decreasing the likelihood of developing a stress granule-related disorder or cancer, and methods for determining the propensity for developing a stress granule-related disorder or cancer, as well as compositions and kits containing one or more PARP inhibitors, one or more PARP activators, one or more PARG activators, and one or more ARH3 activators. | 2013-06-20 |
20130156777 | GLIPR1 INHIBITORS AND THERAPEUTIC USES THEREOF - Featured herein are unique epitopes of human glioma pathogenesis-related protein 1 (hGLIPR-1), nucleic acids encoding the same; inhibitors of the nucleic acids and polypeptides; as well as methods for treating certain cancers and viral infections in a subject by administering to the subject an effective amount of a GLIPR1 inhibitor. | 2013-06-20 |
20130156778 | DENDRITIC CELL INHIBITORY PROTEINS FROM TICKS - The present invention provides a dendritic cell modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian dendritic cells. The invention also provides proteins comprising conserved motifs found in such proteins as well as pharmaceutical compositions comprising the dendritic cell modulatory protein and homologues and active fragments thereof, antibodies thereto and methods of treatment which utilise such proteins, homologues, fragments and antibodies. | 2013-06-20 |
20130156779 | NOVEL ANTIGEN BINDING PROTEINS - The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3. | 2013-06-20 |
20130156780 | Annexin 1 Antibody - The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. | 2013-06-20 |
20130156781 | ANTI-DR4 AGONIST ANTIBODIES - The present invention provides antibodies and antibody fragments that specifically recognize and agonize the death receptor 4 (DR4). Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors. | 2013-06-20 |
20130156782 | Monoclonal Antibodies for Treatment of Cancer - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer. | 2013-06-20 |
20130156783 | IMMUNOTHERAPY TARGETING OF THE SHARED ABNORMAL CONFORMATIONAL STATE OF AMYLOIDOGENIC PEPTIDES/PROTEINS - The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease. | 2013-06-20 |
20130156784 | Compositions Using Antibodies Directed To GPNMB And Uses Thereof - The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein. | 2013-06-20 |
20130156785 | NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES - Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon. | 2013-06-20 |
20130156786 | PEPTIDE OR PEPTIDE COMPLEX BINDING TO 2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME - The present invention relates to a peptide or peptide complex binding to α2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting α2 integrin and a screening method. | 2013-06-20 |
20130156787 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ANGIOGENESIS, AND METHOD FOR SCREENING FOR ACTIVE SUBSTANCES FOR PROMOTING ANGIOGENESIS - The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27. In addition, the present invention relates to a method for screening for active substances for promoting angiogenesis or for active substances for treating an angiogenesis-dependent ailment, the method comprising the following steps: treating vascular endothelial cell lines with each specimen; measuring the content of HSP27 in the respective vascular endothelial cell lines; and selecting a specimen in which the HSP27 content in the vascular endothelial cell lines are decreased as compared to a control group. | 2013-06-20 |
20130156788 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed. | 2013-06-20 |
20130156789 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises:
| 2013-06-20 |
20130156790 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT - The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof. | 2013-06-20 |
20130156791 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS - The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection. | 2013-06-20 |
20130156792 | Uniform field magnetization and targeting of therapeutic formulations - Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage. | 2013-06-20 |
20130156793 | INSULIN-RESISTANCE-IMPROVING DRUG - Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of FSTL3. Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3. | 2013-06-20 |
20130156794 | IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS - A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes. | 2013-06-20 |
20130156795 | METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF - The invention provides for methods for treating nervous system cancers in a subject. The invention further provides methods for treating nervous system tumor cell invasion, migration, proliferation, and angiogenesis associated with nervous system tumors. | 2013-06-20 |
20130156796 | Method of Treatment of Tumors That Are Resistant to EGFR Therapies by EGFR Antibody Cytotoxic Agent Conjugate - The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed. | 2013-06-20 |
20130156797 | Method for Preserving Alum Adjuvants and Alum-Adjuvanted Vaccines - A method for preserving an aluminium-salt adjuvant during freezing or drying comprising freezing or drying an aqueous suspension or solution comprising: (a) an aluminium salt adjuvant; (b) a compound of formula (I) or a physiologically acceptable salt or ester thereof or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (c) optionally, one or more sugars. | 2013-06-20 |
20130156798 | PEPTIDE COMPOSITION - There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods. | 2013-06-20 |
20130156799 | CONTIGUOUS OVERLAPPING PEPTIDES FOR TREATMENT OF BIRCH POLLEN ALLERGY - Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing their ability to bind IgE. | 2013-06-20 |
20130156800 | IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. | 2013-06-20 |
20130156801 | COMPOSITIONS AND METHODS FOR EXOSOME TARGETED EXPRESSION - The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein. | 2013-06-20 |
20130156802 | Cholera Toxin Chimera and its Use as a Staph Vaccine - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 2013-06-20 |
20130156803 | COMPOSITIONS AND METHODS RELATED TO P6 - Disclosed are compositions and methods related to vaccination for AOM and children prone to AOM. | 2013-06-20 |
20130156804 | Porin B (PorB) as a Therapeutic Target for Prevention and Treatment of Infection by Chlamydia - The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit | 2013-06-20 |
20130156805 | CHIMERIC MOMP ANTIGEN - The present invention regards polypeptides capable of eliciting an immunological response that is protective against | 2013-06-20 |
20130156806 | Antigenic Polypeptides of Trichinella and Uses Thereof - The invention relates to novel polypeptides which are recognized by anti- | 2013-06-20 |
20130156807 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR - The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma. | 2013-06-20 |
20130156808 | VACCINE COMPRISING BETA-HERPESVIRUS - The present invention relates to a beta-herpesvirus, preferably a recombinant beta-herpesvirus, wherein the beta-herpesvirus comprises at least one heterologous nucleic acid, wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand. | 2013-06-20 |
20130156809 | Recombinant Bacterium and Uses Thereof - The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided. | 2013-06-20 |
20130156810 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2013-06-20 |
20130156811 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 2013-06-20 |
20130156812 | Composition of Antigen and Method of Sublingual Administration - A method of sublingually administering an effective amount of an antigenic composition to a mammal in order to produce a mucosal and systemic immune response. | 2013-06-20 |
20130156813 | BIOMARKERS FOR PROSTATE CANCER AND METHODS FOR THEIR DETECTION - The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine. | 2013-06-20 |
20130156814 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS - The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9. | 2013-06-20 |
20130156815 | TRANSDERMAL ESTROGEN DEVICE AND DELIVERY - Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described. | 2013-06-20 |
20130156816 | METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE - The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture. | 2013-06-20 |
20130156817 | SURFACE IMMOBILIZED CHAPERONES - A container containing a therapeutic protein, characterized in that chaperones molecules are bound by a molecular linker to an inner surface of the container. The linker being interposed between the surface and the chaperone. | 2013-06-20 |
20130156818 | METHODS AND COMPOSITIONS FOR CONTROLLING ASSEMBLY OF VIRAL PROTEINS - Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage. | 2013-06-20 |
20130156819 | ISOLATION OF MESENCHYMAL STEM CELLS - The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues. | 2013-06-20 |
20130156820 | PRODUCTION METHOD OF TISSUE REGENERATION MATERIAL AND TISSUE REGENERATION MATERIAL - Provided is a production method of a tissue regeneration material whereby a cell suspension can be seeded and cultured on a porous support having relatively large pores. The method comprises: contacting a porous body to a holding plate having a contact angle to water of 15 to 90°, the porous body being formed of a bioabsorbable polymer material, having a thickness of 2 to 100 mm, an interconnected porous structure with a pore diameter of 180 to 3500 μm and an average pore diameter of 350 to 2000 μm, a porosity of 60 to 95%, and a compressive strength of 0.05 to 1 MPa, and being filled with a cell suspension having a cell density of 5×10 | 2013-06-20 |
20130156821 | SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 2013-06-20 |
20130156822 | DRUG DELIVERY SYSTEM AND METHOD FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASE - Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease. | 2013-06-20 |
20130156823 | Excipient-free Aerosol Formulation - Methods and compositions for producing formulations for orally inhaled benzodiazepines that do not require the presence of a surface modifier are described. The formulations are useful in the treatment of epileptic seizures. | 2013-06-20 |
20130156824 | PROTECTIVE WOUND DRESSING DEVICE FOR ORAL AND PHARYNGEAL SPACE - The present invention provides a wound dressing comprising a tessellated water-soluble molding matrix comprised of a polymer selected from the group consisting of polyvinyl alcohol, gelatin, and mixtures thereof and a 1,1-disubstituted ethylene monomer. The present invention further provides methods of using the wound dressing and kits containing the wound dressing. | 2013-06-20 |
20130156825 | Modafinil Formulations - The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns. | 2013-06-20 |
20130156826 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN - The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I). | 2013-06-20 |
20130156827 | SODIUM ALGINATE CROSSLINKED SLOW-RELEASE MOXIFLOXACIN MICROSPHERE, THE PREPARATION METHOD AND THE USE THEREOF, AND TARGET VASCULAR OCCLUSIVE AGENT OF THE MICROSPHERE - A sodium alginate crosslinked slow-released moxifloxacin microsphere, the preparation method of the microsphere, a vascular target embolus containing the microsphere and the use of the microsphere in preparing the vascular target embolus. The microsphere contains moxifloxacin, a drug carrier, a adsorbent, a reinforcing agent and a solidifying agent, wherein the drug carrier is sodium alginate, the adsorbent is albumin prepared from human plasma or bovine serum albumin, the reinforcing agent is gelatin or hyaluronic acid, and the solidifying agent is a divalent metal cation chosen from calcium salt or barium salt. | 2013-06-20 |
20130156828 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same - A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6α, 11β, 16α, 17α)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1, 4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhitbits a Relative Humidity of from 20% to 40%. | 2013-06-20 |
20130156829 | COATING AGENT FOR PHARMACEUTICAL SOLID PREPARATION, PHARMACEUTICAL FILM FORMULATION, AND COATED PHARMACEUTICAL SOLID PREPARATION - A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4. | 2013-06-20 |
20130156830 | Composite Particles, Compositions And Methods - Composite particulates, topical composition containing composite particulates, methods for improving the appearance of skin depth, dimensionality or undertones; a method for improving the ashy, chalky or mask-like appearance of color cosmetic compositions on the skin; and a method for reducing the number of shades in a color cosmetic shade range by formulating the cosmetic with composite particulates. | 2013-06-20 |
20130156831 | Thickening Composition And Cosmetic Preparation Containing The Same - To provide a thickening composition which exhibits excellent feelings in use, namely, exhibits excellent freshness, non-stickiness and blend into skin feeling, and does not leave any residue on skin, which can stably keep the viscosity thereof in a low to moderate-level viscosity range and which, even when a salt-type ingredient is incorporated therein, does not undergo viscosity change, and also a cosmetic preparation containing the composition. A thickening composition which comprises (a) from 0.1 to 2% by mass of a specific hydrophobic denatured polyether urethane (associative thickener) and (b) from 0.1 to 2% by mass of a microgel to be obtained by grinding a gel of a hydrophilic compound having a gelling capability, in a ratio of component (a)/component (b) of from 0.1/0.9 to 0.9 to 0.1 (by mass), and which has a viscosity of from 50 to 50,000 mPa·s (with BL-type viscometer, 12 rotations, 25° C.); and a cosmetic preparation containing the thickening composition. | 2013-06-20 |
20130156832 | EUDERMIC COMPOSITIONS - Eudermic composition comprising at least one eudermically active principle, at least one vehicle for said active principle, and porous silica particles, wherein the active principle is contained in at least one pore of at least a first portion of such silica particles and in the vehicle. | 2013-06-20 |
20130156833 | COSMETIC COMPOSITION COMPRISING PEBA - The present invention relates to a composition comprising from 0.1 to 30% by weight of copolymer comprising polyether blocks and polyamide blocks (PEBA), and from 70 to 99.9% by weight of a medium which is acceptable in the cosmetics industry, in the perfumery industry and/or in the pharmaceutical industry. The present invention also relates in particular to a process for incorporating a copolymer comprising polyether blocks and polyamide blocks into a cosmetic, perfumery and/or pharmaceutical medium. The subject matter of the present invention is also the use of a copolymer comprising polyether blocks and polyamide blocks (PEBA) for producing a cosmetic, pharmaceutical or perfumery product, said PEBA being incorporated in the form of a composition in accordance with the invention. | 2013-06-20 |
20130156834 | PROCESS FOR TREATING SOL-GEL CAPSULES - The present invention relates to a process for treating sol-gel capsules comprising a cosmetic or pharmaceutical active material with an inorganic material, as well as sol-gel capsules produced by a process according to the present invention and formulations comprising such sol-gel capsules. | 2013-06-20 |
20130156835 | NOVEL FORMULATIONS OF ACTIVE INGREDIENT(S) OF PLANT ORIGIN OR SYNTHETIC ANALOGUES THEREOF OR OF EXTRACT(S) OF PLANT ORIGIN CONTAINING SAME, AND OF LECITHIN - The present invention relates to a composition comprising one or more active ingredients of plant origin, or their synthetic analogues or extract(s) of plant origin containing them, encapsulated by the lecithin in an aqueous solution. | 2013-06-20 |
20130156836 | Chitosan Bornet - The invention relates to a chitosan as a micronized powder, to its use for controlling certain yeasts, such as | 2013-06-20 |
20130156837 | CONTROL OF ARTHROPOD INFESTATION USING PARTICLES COMPRISING AN ENTOMOPATHOGEN AND WAX - Composite particles containing hydrophobic particles and spores of an entomopathogenic fungus that are capable of germinating on the cuticle of a grain storage arthropod, dry powder compositions comprising such composite particles, methods of producing such compositions and methods and uses thereof. | 2013-06-20 |
20130156838 | NOVEL BIOCIDE COMPOSITION - The present invention relates to a novel biocide composition for use in gravity fed water purification devices and suitable for purifying water for drinking purposes and a process for preparing the novel biocide composition. The biocide tablet composition comprises one or more halogenated 5, 5-dialkylhydantoin compound; a chlorine biocide compound selected from trichloroisocyanuric acid (TCCA) or sodium dichloroisocyanurate (NaDCC) or mixtures thereof; 0.1-1.0% water soluble boron containing compound; wherein the ratio between the halogenated 5, 5-dialkylhydantoin compound and chlorine biocide compound is in the range 85:15 to 65:35 and the average particle size of the halogenated 5, 5-dialkylhydantoin compound and chlorine biocide compound is in the range 400 to1200 microns. | 2013-06-20 |
20130156839 | BROAD SPECTRUM PEST REPELLENT COMPOSITIONS AND PEST MANAGEMENT SYSTEM - The present invention provides compositions and methods for the control and management of wildlife populations (including domesticated animals) and pests such as birds including geese, deer and other herbivore such as rabbits, ground hogs, raccoons, moose and elk, tunneling animals such as moles, voles and gophers and insects, carnivores and other organisms. Specifically provided are geraniol oil-based formulations which may be applied to natural or artificial surfaces. Also provided are pest control systems incorporating the use of repellent or attractant formulations. | 2013-06-20 |
20130156840 | IMPLANTABLE INTRAOCULAR DRUG DELIVERY APPARATUS, SYSTEM AND METHOD - The present invention relates to an apparatus, system and method for, and for providing, intraocular delivery of an active agent. The apparatus, system and method may include an implantable scaffold and an active agent associated with the implantable scaffold. The implantable scaffold and the active agent may be configured to be completely contained within the eye upon implantation. The implantable scaffold may be a mechanical scaffold, or the implantable scaffold may be a chemical scaffold. | 2013-06-20 |
20130156841 | METHOD OF REDUCING INCIDENCE OF INTRAOCULAR PRESSURE ASSOCIATED WITH INTRAOCULAR USE OF CORTICOSTEROIDS - A method of treating an ocular disease in a subject using a corticosteroid with reduced incidence of intraocular pressure lowering surgery comprises injecting an intravitreal insert capable of providing a therapeutic effect for an extended period of time. The intravitreal insert delivers sustained sub-microgram levels of corticosteroid. | 2013-06-20 |
20130156842 | BIOADHESIVE DRUG FORMULATIONS FOR ORAL TRANSMUCOSAL DELIVERY - Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same. | 2013-06-20 |
20130156843 | Artificial Hair Filament Having Antibacterial and Antifungal Properties, Method and Device for Preparing the Same - An artificial hair filament having a core/sheath structure is provided. The artificial hair filament has excellent antibacterial and antifungal effects since antibacterial and antifungal nanoparticles are included in the sheath structure of the artificial hair filament. Here, the antibacterial and antifungal effects can last for a long period of time. A contact-type drug-treating roller and an ultrasonic spraying machine can be used to provide the artificial hair filament with the antibacterial and antifungal effects. In the artificial hair filament, the sheath structure is formed so that the sheath structure occupies 5 to 20% of an entire filament diameter, thereby exhibiting desirable antibacterial and antifungal effects. Therefore, degradation of the antibacterial properties and antifungal properties with time can be prevented. | 2013-06-20 |
20130156844 | METHODS FOR STEPWISE DEPOSITION OF SILK FIBROIN COATINGS - The invention provides a method for the controlled assembly of layered silk fibroin coatings using aqueous silk fibroin material. The methods described herein can be used to coat substrates of any material, shape, or size. Importantly, the described methods enable control of the biomaterial surface chemistry, thickness, morphology and structure using layered thin film coatings, or bulk coatings. Furthermore, the methods can be performed in all water and do not require intensive chemical processing enabling controlled entrapment of labile molecules such as, drugs, cytokines, and even cells or viruses to generate functional coatings that can be used in a variety of applications. | 2013-06-20 |
20130156845 | LIPID FORMULATED SINGLE STRANDED RNA - The present invention provides compositions comprising a nucleic acid lipid particle and an oligomeric compound and uses thereof. In certain embodiments, such compositions are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds. | 2013-06-20 |
20130156846 | L-SERINE COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD). | 2013-06-20 |
20130156847 | METHODS OF INDUCING CELL DIFFERENTIATION WITH PLACENTAL EXTRACTS - Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described. | 2013-06-20 |
20130156848 | COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS - Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed. | 2013-06-20 |
20130156849 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS - The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity. | 2013-06-20 |
20130156850 | APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I. | 2013-06-20 |
20130156851 | LIPOMACROCYCLES AND USES THEREOF - What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: | 2013-06-20 |
20130156852 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2013-06-20 |
20130156853 | Liquid Compositions of Insoluble Drugs and Preparation Methods Thereof - A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10%, oil for injection 0%-20%, phospholipid 10-80%, solvent 20-89%. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly. | 2013-06-20 |
20130156854 | Controlled Release Pharmaceutical Compositions of Milnacipran - A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts there—of is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents. | 2013-06-20 |
20130156855 | ACNE TREATMENT - One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine. | 2013-06-20 |
20130156856 | ANTICOAGULANT-CONJUGATED CARBON NANOCAPSULE, ANTITHROMBOTIC AGENT CONTAINING THEREOF - The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided. | 2013-06-20 |
20130156857 | Pharmaceutical Compositions Containing Diacerein - A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed. | 2013-06-20 |
20130156858 | Formulations Preserving Bioactivity and Methods of Their Preparation - A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines. | 2013-06-20 |
20130156859 | IMMUNOGENIC COMPOSITION - An immunogenic composition includes as effective ingredients: an immunogenic micro-particle composed of an antigen-adjuvant microparticle complex wherein an antigen(s) is/are encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydro-phobic segment(s) is/are poly(hydroxy acid); and a surfactant encapsulated in the immunogenic microparticle. | 2013-06-20 |
20130156860 | METHOD FOR THE PREVENTION OF CHRONIC INFLAMMATION ASSOCIATED DISEASES - The present invention is related to a method for the prevention and possibly the treatment of chronic diseases, preferably inflammatory associated chronic diseases that may affect an animal including a human, by the administration of a sufficient amount of a (functional) food or feed to the diet of this animal. | 2013-06-20 |
20130156861 | ALCOHOLIC INJURY MITIGATING AGENT - The present invention relates to an alcoholic injury mitigating agent comprising krill oil as an active ingredient. The krill oil preferably comprises phospholipids in an amount of at least 30% by weight, ω3 polyunsaturated fatty acids in an amount of at least 5% by weight of the total fatty acids, eicosapentaenoic acid in an amount of at least 2% by weight of the total fatty acids, or docosahexaenoic acid in an amount of at least 1% by weight of the total fatty acids. | 2013-06-20 |
20130156862 | Extracellular Matrix-Derived Gels and Related Methods - Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient. | 2013-06-20 |
20130156863 | METHODS OF PREPARING CHORION TISSUE AND PRODUCTS DERIVED THEREFROM - Disclosed herein, in certain instances, are tissue grafts derived from chorion or amnio-chorion. Further disclosed herein, in certain instances, are use for tissue grafts derived from chorion or amnio-chorion. | 2013-06-20 |
20130156864 | Inorganic Cement for Biomedical uses, Preparation Method Thereof and Use of Same - The present invention relates to a cement based on magnesium sodium phosphate with clinical applications in bone surgery and odontology. This cement has an intrinsic antimicrobial effect as its main property. It also has a fast setting time, along with a high short-term compressive strength. Another property inherent to these cements is their adhesive character. | 2013-06-20 |